Kinase inhibitors targeting the B-cell receptor (BCR) are now prominent in the treatment of
chronic lymphocytic leukemia (CLL). We have focused here on interleukin 4 (IL-4), a cytokine …

Objectives To combine spontaneously reported data from multiple countries to estimate reporting
rate, and better understand risk factors for myocarditis and pericarditis following COVID-…

Antigenic stimulation via the B-cell receptor (BCR) is a major driver of the proliferation and
survival of chronic lymphocytic leukemia (CLL) cells. However, the precise mechanisms by …

Loss-of-function mutations in KMT2D are a striking feature of germinal center (GC)
lymphomas, resulting in decreased histone 3 lysine 4 (H3K4) methylation and altered gene …

Purpose: The DEAD-box RNA helicase eIF4A1 carries out the key enzymatic step of cap-dependent
translation initiation and is a well-established target for cancer therapy, but no drug …

Signaling via the B-cell receptor (BCR) is a key driver and therapeutic target in chronic
lymphocytic leukemia (CLL). BCR stimulation of CLL cells induces expression of eIF4A, an …

Objectives To determine whether spontaneous reporting rates of myocarditis and pericarditis
differed in immunocompromised patients compared with the whole population overall, and …

NOTCH1 mutations in chronic lymphocytic leukemia (CLL) lead to accumulation of NOTCH1
intracellular domain (NICD) and prolong signaling. These mutations associate with a more …

Background Real-world data on early treatment of coronavirus disease 2019 (COVID-19)
outpatients with newly approved therapies are sparse. Aim To explore the pattern of use of …

… View ORCID ProfileSamantha Lane, Alison Yeomans, Saad Shakir … Samantha Lane
and Alison Yeomans have no conflicts of interest with regard to this study. …